Literature DB >> 16707590

Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway.

Garth Powis1, Nathan Ihle, D Lynn Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16707590     DOI： 10.1158/1078-0432.CCR-06-0617

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  18 in total

Review 1.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.

Authors:  Ho-Shin Gwak; Takashi Shingu; Vaibhav Chumbalkar; Yeo-Hyeon Hwang; Robert DeJournett; Khatri Latha; Dimpy Koul; W K Alfred Yung; Garth Powis; Nicholas P Farrell; Oliver Bögler
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

Review 3.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

4.  Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

Authors:  Richard Gorlick; John M Maris; Peter J Houghton; Richard Lock; Hernan Carol; Raushan T Kurmasheva; E Anders Kolb; Stephen T Keir; C Patrick Reynolds; Min H Kang; Catherine A Billups; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2011-11-18       Impact factor: 3.167

5.  Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

Authors:  Hernan Carol; Christopher L Morton; Richard Gorlick; E Anders Kolb; Stephen T Keir; C Patrick Reynolds; Min H Kang; John M Maris; Catherine Billups; Malcolm A Smith; Peter J Houghton; Richard B Lock
Journal:  Pediatr Blood Cancer       Date:  2010-08-25       Impact factor: 3.167

6.  The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma.

Authors:  Erin C Ward; Anna V Hoekstra; Leen J Blok; P Hanifi-Moghaddam; John R Lurain; Diljeet K Singh; Barbara M Buttin; Julian C Schink; J Julie Kim
Journal:  Endocrinology       Date:  2007-12-20       Impact factor: 4.736

7.  Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance.

Authors:  Jing Lu; Ming Tan; Wen-Chien Huang; Ping Li; Hua Guo; Ling-Ming Tseng; Xiao-hua Su; Wen-Tao Yang; Warapen Treekitkarnmongkol; Michael Andreeff; Fraser Symmans; Dihua Yu
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

8.  The antiproliferative cytostatic effects of a self-activating viridin prodrug.

Authors:  Adam Smith; Joseph Blois; Hushan Yuan; Elena Aikawa; Christian Ellson; Jose-Luiz Figueiredo; Ralph Weissleder; Rainer Kohler; Michael B Yaffe; Lewis C Cantley; Lee Josephson
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

9.  Inhibition of Akt sensitises neuroblastoma cells to gold(III) porphyrin 1a, a novel antitumour drug induced apoptosis and growth inhibition.

Authors:  W Li; Y Xie; R W-Y Sun; Q Liu; J Young; W-Y Yu; C-M Che; P K Tam; Y Ren
Journal:  Br J Cancer       Date:  2009-06-23       Impact factor: 7.640

10.  Inhibition of Cell Proliferation and MAP Kinase and Akt Pathways in Oral Squamous cell Carcinoma by Genistein and Biochanin A.

Authors:  Tara L Johnson; Maria B Lai; James C K Lai; Alok Bhushan
Journal:  Evid Based Complement Alternat Med       Date:  2008-02-29       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.